General
Kano Therapeutics enables safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials.
Developer of a biotechnological production platform intended to expand the reach of genome-editing-based therapies through the development of transformational biomaterials. The company uses DNA nanotechnology and synthetic biology to design and engineer novel gene vectors that carry genetic information, providing pharmaceutical and synthetic biology companies with gene delivery and vaccine construct knowledge.